Melrose Park, USA

Fresenius Kabi USA develops, manufactures and markets injectable pharmaceuticals, with important products in the oncology, anti-infective, anaesthetic/analgesic and critical care fields. Fresenius Kabi USA operates out of two sites, located in upstate New York and Illinois.

The acquisition of the Melrose Park facility in 2008 has given Fresenius Kabi an entry into the U.S. pharmaceutical market and a leading position in the global I.V. generics industry. The company offers one of the most comprehensive portfolios of products used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a complete range of dosage formulations. Integrating this production facility into the Fresenius Kabi global production network means that the group now has a presence with substantial manufacturing expertise and technical capabilities in North America.

Our production facility in Melrose Park, Illinois, is located in the outskirts of Chicago and just 5 miles from O`Hare International Airport. The plant is in a general industrial area and employs approximately 700 people. Besides production, laboratory, office and warehouse facilities the plant also has a state-of-the-art microbiology laboratory, opened in November 2009.

Fresenius Kabi is able to market its entire product range in the US, and furthermore through its international marketing and sales network to sell the products herein manufactured globally. But the acquisition has not only enlarged Fresenius Kabi‘s internal capabilities – it has also broadened the possibilities and capabilities of Fresenius Kabi Contract Manufacturing. All the technological capabilities of the plant are also available for external customers, depending on capacity.



  • Lyophilization
  • Aseptic liquid filling
  • Aseptic SCF syringes
  • Terminal sterilization


  • Oncology
  • Anti-infective
  • Anaesthetic
  • Analgesic 
  • Critical care



  • US-FDA


  • Worldwide